Then, three key pathways, including the synthesis and degradation of ketone bodies, glycerophospholipid metabolism and fatty acid degradation, were recognized as potential biomarkers for recognizing MGMT promoter unmethylated GBM and MGMT promoter methylation positive GBM from GBM patient samples, with areas under the curve of 0.7895, 0.7326 and 0.7026, respectively. The gene discussed is MGMT; the disease is glioblastoma.